title: Population pharmacokinetic analysis of voriconazole from a pharmacokinetic study with immunocompromised Japanese pediatric subjects.
abstract: A population pharmacokinetic (PK) analysis was conducted to characterize the voriconazole pharmacokinetic profiles in immunocompromised Japanese pediatric subjects and to compare them to those in immunocompromised non-Japanese pediatric subjects. A previously developed two-compartment pharmacokinetic model with first-order absorption and mixed linear and nonlinear elimination adequately described the voriconazole intravenous and oral data from Japanese pediatric subjects with few modifications. Bayesian priors were applied to this analysis by using the NONMEM routine NWPRI, which allowed priors for the fixed-effect parameter vector and variance matrix of the random-effect parameters to be a normal distribution and an inverse Wishart distribution, respectively. Large intersubject variabilities in oral bioavailability and voriconazole exposure were observed in these pediatric subjects. The mean oral bioavailability estimated in Japanese pediatric subjects was 73% (range, 17% to 99%), which is consistent with the reported estimates of 64% in the previous model and less than what was originally estimated for healthy adults-96%. Voriconazole exposures in Japanese pediatric subjects were generally comparable to those in non-Japanese pediatric subjects receiving the same dosing regimens, given the large intersubject variability. Consistent with the previous findings, the CYP2C19 genotyping status did not have a clinically relevant effect on voriconazole exposure in Japanese pediatric subjects, although it was identified as a covariate in the model to help explain the intersubject variability in voriconazole exposure. The CYP2C19 genotyping status alone does not warrant dose adjustment of voriconazole. No other factors besides age and weight were identified to explain the PK variability of voriconazole.
authors: Clinical Pharmacology, Pfizer Japan Inc., Tokyo, Japan chieko.muto@pfizer.com.
authors: Chieko
authors: C
authors: Muto
authors: Clinical Pharmacology, Pfizer Japan Inc., Tokyo, Japan.
authors: Satoshi
authors: S
authors: Shoji
authors: Clinical Pharmacology, Pfizer Japan Inc., Tokyo, Japan.
authors: Yoshiro
authors: Y
authors: Tomono
authors: Clinical Pharmacology, Global Established Pharma Business, Pfizer Inc., Groton, Connecticut, USA.
authors: Ping
authors: P
authors: Liu
mesh_terms: D000935:Antifungal Agents / Q000493:pharmacokinetics*; D065731:Cytochrome P-450 CYP2C19 / Q000235:genetics; D004305:Dose-Response Relationship, Drug; D005838:Genotype; D006801:Humans; D016867:Immunocompromised Host; D007564:Japan; D065819:Voriconazole / Q000493:pharmacokinetics*
chemical_list: D000935:Antifungal Agents; D065731:Cytochrome P-450 CYP2C19; D065819:Voriconazole